Share on StockTwits
 

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) CEO Keith Leonard sold 12,480 shares of KYTHERA Biopharmaceuticals stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $37.38, for a total transaction of $466,502.40. Following the transaction, the chief executive officer now directly owns 4,461 shares in the company, valued at approximately $166,752. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

A number of analysts have recently weighed in on KYTH shares. Analysts at FBR & Co. initiated coverage on shares of KYTHERA Biopharmaceuticals in a research note to investors on Wednesday, October 30th. They set an “outperform” rating on the stock. Separately, analysts at FBR Capital Markets initiated coverage on shares of KYTHERA Biopharmaceuticals in a research note to investors on Wednesday, October 30th. They set an “outperform” rating and a $58.00 price target on the stock. Finally, analysts at Bank of America Corp. initiated coverage on shares of KYTHERA Biopharmaceuticals in a research note to investors on Friday, October 25th. They set a “buy” rating on the stock. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. KYTHERA Biopharmaceuticals presently has an average rating of “Buy” and a consensus price target of $45.33.

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) traded down 1.53% on Friday, hitting $36.73. 433,093 shares of the company’s stock traded hands. KYTHERA Biopharmaceuticals has a 52 week low of $14.07 and a 52 week high of $47.85. The stock has a 50-day moving average of $38.98 and a 200-day moving average of $34.9. The company’s market cap is $786.0 million.

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) last released its earnings data on Thursday, November 14th. The company reported ($0.62) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.72) by $0.10.

KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.